Opinion|Videos|August 5, 2024
Applying EHA 2024 Data to Switching and Sequencing Treatments for CLL & Impact of Toxicities
Experts analyze recent real-world evidence on treatment patterns, focusing on the strategies and outcomes of switching and sequencing therapies in chronic lymphocytic leukemia patients.
Advertisement
Episodes in this series
- Briefly comment on recent real world data regarding switching and sequencing to next line of therapy in patients with CLL. (
Pinilla-Ibarz, et al. EHA 2024. Abstract P697 )
- How do you interpret these data and how may they influence your overall treatment approach?
Advertisement
Related to this article
Lisaftoclax plus acalabrutinib earned breakthrough therapy status in China for untreated CLL/SLL.
The top 5 OncLive TV videos of the week cover insights in multiple myeloma, HR+ breast cancer, CAR T-cell therapy, CLL, and oral SERDs.
The top 5 OncLive TV videos of the week.
Read a refresh of hematologic cancer FDA and global regulatory news from September 2026.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Full Approval to Pembrolizumab for Unresectable/Metastatic TMB-H Solid Tumors
2
HER2+ mCRC Treatment Sequencing Favors Tucatinib Plus Trastuzumab Before T-DXd
3
Polls Reveal Top Picks for Lung Cancer Abstracts of Interest at ESMO 2026
4
Poll Results Highlight Gynecologic Cancer Abstracts of Interest at ESMO 2026
5